FOLH1 and neoplasm: Clinical studies evaluated the potential of PSMA imaging using radiolabeled PSMA antibodies (ProstaScint®, J591) and ligands (namely [68 Ga]Ga-PSMA-11 and [18F]F-PSMA-1007), mainly by positron emission tomography (PET), revealing higher tumor detection rates and higher tumor-to-background ratios compared to conventional imaging modalities [9–12].